XL019
XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1. (In Vivo) :XL019 (100-300 mg/kg; p.o.; twice daily for 14 days) inhibits HEL.92.1.7 xenograft tumor growth.XL019 (10 mg/kg) treatment shows that the Cmax, t1/2 and Vd were 5.24 μM, 1.94 hours, 5.319 L/kg, respectively.
Product Specifications
CAS Number
945755-56-6
Product Name Alternative
XL019 | XL-019 | XL 019
Purity
>98% (HPLC)
Solubility
DMSO: 16 mg/mL (35.99 mM)
Smiles
O=C ([C@H]1NCCC1) NC2=CC=C (C3=NC (NC4=CC=C (N5CCOCC5) C=C4) =NC=C3) C=C2
Molecular Formula
C25H28N6O2
Molecular Weight
444.53
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(S) -N- (4- (2- ((4-morpholinophenyl) amino) pyrimidin-4-yl) phenyl) pyrrolidine-2-carboxamide
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS7078614 Inquire
Recombinant Pseudomonas fluorescens ATP synthase subunit b (atpF), partial
Sign In for Pricing
View Details 
bsm-54718R-BF405 100 µL
IRF4 Recombinant Antibody, AbBy Fluor™ 405 Conjugated
Sign In for Pricing
View Details LS007586-100ug 100 µg
ZKSCAN1 (NM_003439) Human Over-expression Lysate
Sign In for Pricing
View Details